Form 4: CytomX CEO Sells Over 100K Shares Under 10b5-1 Plan

CytomX Therapeutics CEO Sean A. McCarthy sold 101,793 shares of Class A Common Stock for $4.5377 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• Sean A. McCarthy, CEO and Director of CytomX Therapeutics, Inc. (CTMX), sold 101,793 shares of Class A Common Stock.
• The sale occurred on November 6, 2025, at a weighted average price of $4.5377 per share.
• This transaction was executed under a Rule 10b5-1 trading plan, which was adopted on August 27, 2024.
• Following the sale, McCarthy directly beneficially owns 987,891 shares, which includes 488,750 restricted stock units.
• Additionally, 93,158 shares are indirectly beneficially owned through the Sean A. McCarthy 2018 Trust.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by the CEO, even under a pre-arranged 10b5-1 plan, can be interpreted as a neutral to slightly negative signal regarding management's immediate outlook or personal diversification strategy. It does not reflect new positive developments for the company.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not necessarily reactive transaction.

Negatives

• A significant sale of 101,793 shares by the CEO could be perceived negatively by investors, potentially signaling a lack of confidence or a desire to diversify personal holdings.

Future Outlook

NA

Management Comments

• The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 27, 2024.
• This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price.

Industry Context

This Form 4 filing details an insider stock transaction for CytomX Therapeutics, a biotechnology company. Such sales by executives are common for personal financial planning, especially when executed under a 10b5-1 plan, which provides an affirmative defense against insider trading allegations. While not directly indicative of industry trends, it reflects individual executive financial management within the biotech sector.

Comparison to Industry Standards

• Insider sales, particularly by CEOs, are a common occurrence across all industries, including biotechnology. The use of a Rule 10b5-1 trading plan aligns with best practices for executives to sell shares in a pre-scheduled, transparent manner, mitigating concerns about opportunistic trading. Many executives at comparable biotech firms like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals also utilize 10b5-1 plans for their personal stock transactions.

Stakeholder Impact

• Shareholders: May interpret the CEO's sale as a signal, potentially influencing their investment decisions. The 10b5-1 plan context helps to reduce speculative negative interpretations.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

While the CEO's sale of shares is a notable event, its execution under a pre-arranged 10b5-1 plan suggests a planned personal financial move rather than a reaction to new negative company developments. Without additional information on the company's operational performance or strategic outlook, this single transaction does not warrant a change from a 'hold' position. Investors should monitor future company announcements and financial reports for more comprehensive insights.

Keywords

CytomX Therapeutics, CTMX, Sean A. McCarthy, Insider Sale, Form 4, 10b5-1 Plan, CEO, Stock Transaction, Biotechnology, Pharmaceuticals